MBX · MBX Biosciences, Inc.

Track MBX — free

$66.33 -0.02 (-0.03%) At close · Aug 21

Market Cap

$3.18B

48.16M

Up next

Next earnings call

Oct 20, 2026 Est · unconfirmed · in 8 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.1 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +71%

above

Price vs 50-day avg +13%

above

RSI (14) 55

neutral

MACD trend Negative

52-week position 93%

near high

Volume (OBV) Bearish div.

distributing

Momentum

relative strength

Very Strong

1-month return +7%

trailing

6-month return +101%

trailing

YTD return +110%

this year

Relative strength +90%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $59 › 200d $39 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +40 funds added

Insider flow Distributing

Net -$24.3K over 90 days · 100% sells

Short interest Falling

10.77% of float · ▼ -10.2% MoM · 8.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

174 holders — near 2-yr high, broad support

Squeeze score 70

elevated · 0–100

Fundamentals

Strong

EPS growth +59%

Y/Y

Free cash flow $-81.9M

Balance sheet $75.3M

net cash

Quant / Vol

risk profile

Very High

Volatility 131%

annualized · 1-yr

Max drawdown −38%

past year

ATR 5.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+71% Bullish

Price vs 50-day avg

+13% Bullish

RSI (14)

55 Neutral

MACD trend

Negative Bearish

52-week position

93% Bullish

Volume (OBV)

Bearish div. Bearish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $59 › 200d $39 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +40 funds added

Insider flow Distributing

Net -$24.3K over 90 days · 100% sells

Short interest Falling

10.77% of float · ▼ -10.2% MoM · 8.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

174 holders — near 2-yr high, broad support

Price context

position in its 52-week range

Range low $10 Now $66 · 93% Range high $71

vs 200-day avg +71% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Pro forma cash and investments	$459.1M	as of December 31, 2025	—
cash, cash equivalents and marketable securities	$373.7M	as of December 31, 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
MBX MBX Biosciences, Inc. this stock	$3.18B	+110.3%	—	—	10.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+20.9%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$85.87B	+8.1%	+20.8%	20.7	3.3%
ARGX Argenx SE	$64.56B	+23.6%	—	—	2.1%
CSLLY Csl Ltd	$58.31B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

174

% held: 116.3%
Net QoQ: +3.3M sh
Top holder: Frazier Life Sciences Man…

Held Float

View

Held by Funds

Fund positions

175

View

Short & Settlement

Short Interest Falling

Shares short

5.2M

Days to cover: 8.5d
Change: -588.1K sh

View

Short Volume

Short vol %

64%

As of: Aug 21, 2026

Short Total

View

Fails to Deliver

FTD shares

2.3K

Value: $142.5K
As of: Jul 27, 2026

View

Off-Exchange

Off-exchange %

48.1%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$24.3K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-87.0M

EPS diluted: $-2.38

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 19

View

Proposed Sales

Value

$255.7K

Shares: 3.7K
Filed: Aug 17, 2026

View

Exempt Offerings

Offering

$115.2M

Filed: Nov 18, 2022

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
MBX	-3.3%	+7.0%	+101.2%	+0.6%	+110.3%
SPY	-1.4%	+3.6%	+11.6%	+2.5%	+12.3%
vs SPY	-1.9%	+3.4%	+89.6%	-1.9%	+98.0%

Key facts CIK 1776111 CUSIP 55287L101 13F (30d) 167 filings 164 filers Visit website Investor relations

MBX · MBX Biosciences, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance